| 1 |
Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study [J]. Lancet Public Health, 2020, 5(12): e661-e671.
|
| 2 |
Cong L, Ren Y, Wang Y, et al. Mild cognitive impairment among rural-dwelling older adults in China: a community-based study [J]. Alzheimers Dement, 2023, 19(1): 56-66.
|
| 3 |
Chen P, Cai H, Bai W, et al. Global prevalence of mild cognitive impairment among older adults living in nursing homes: a meta-analysis and systematic review of epidemiological surveys [J]. Transl Psychiatry, 2023, 13(1): 88.
|
| 4 |
Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier [J]. Arterioscler Thromb Vasc Biol, 2004, 24(5): 806-815.
|
| 5 |
Tint GS, Batta AK, Xu G, et al. The Smith-Lemli-Opitz syndrome: a potentially fatal birth defect caused by a block in the last enzymatic step in cholesterol biosynthesis [J]. Subcell Biochem, 1997, 28: 117-144.
|
| 6 |
Jira PE, Waterham HR, Wanders RJA, et al. Smith-Lemli-Opitz syndrome and the DHCR7 gene [J]. Ann Hum Genet, 2003, 67(Pt 3): 269-280.
|
| 7 |
Fanning S, Haque A, Imberdis T, et al. Lipidomic analysis of α-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for parkinson treatment [J]. Mol Cell, 2019, 73(5): 1001-1014. e8.
|
| 8 |
Shimabukuro MK, Langhi LGP, Cordeiro I, et al. Lipid-laden cells differentially distributed in the aging brain are functionally active and correspond to distinct phenotypes [J]. Sci Rep, 2016, 6: 23795.
|
| 9 |
Mapstone M, Cheema AK, Fiandaca MS, et al. Plasma phospholipids identify antecedent memory impairment in older adults [J]. Nat Med, 2014, 20(4): 415-418.
|
| 10 |
Kim KY, Shin KY, Chang KA. Potential biomarkers for post-stroke cognitive impairment: a systematic review and meta-analysis [J]. Int J Mol Sci, 2022, 23(2): 602.
|
| 11 |
Svensson T, Sawada N, Mimura M, et al. The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up [J]. Transl Psychiatry, 2019, 9(1): 26.
|
| 12 |
Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being [J]. Am J Med, 2000, 108(7): 538-546.
|
| 13 |
Strom BL, Schinnar R, Karlawish J, et al. Statin therapy and risk of acute memory impairment [J]. JAMA Intern Med, 2015, 175(8): 1399-1405.
|
| 14 |
Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association [J]. Arterioscler Thromb Vasc Biol, 2023, 43(10): e404-e442.
|
| 15 |
Fernández-Calle R, Konings SC, Frontiñán-Rubio J, et al. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases [J]. Mol Neurodegener, 2022, 17(1): 62.
|
| 16 |
Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a "thrifty" allele? [J]. Ann Hum Genet, 1999, 63(Pt 4): 301-310.
|
| 17 |
Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis [J]. Biol Psychiatry, 2015, 77(1): 43-51.
|
| 18 |
Jia J, Zhao T, Liu Z, et al. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study [J]. BMJ, 2023, 380: e072691.
|
| 19 |
Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia [J]. Sci Transl Med, 2021, 13(583): eaaz4564.
|
| 20 |
Blanchard JW, Akay LA, Davila-Velderrain J, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes [J]. Nature, 2022, 611(7937): 769-779.
|
| 21 |
Park M, Lee HP, Kim J, et al. Brain myelin water fraction is associated with APOE4 allele status in patients with cognitive impairment [J]. J Neuroimaging, 2022, 32(3): 521-529.
|
| 22 |
Babiker A, Dzeletovic S, Wiklund B, et al. Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid [J]. Scand J Clin Lab Invest, 2005, 65(5): 365-375.
|
| 23 |
Parini P, Johansson L, Bröijersén A, et al. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system [J]. Eur J Clin Invest, 2006, 36(2): 98-104.
|
| 24 |
Ismail MAM, Mateos L, Maioli S, et al. 27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation [J]. J Exp Med, 2017, 214(3): 699-717.
|
| 25 |
Heverin M, Maioli S, Pham T, et al. 27-hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice [J]. Behav Brain Res, 2015, 278: 356-359.
|
| 26 |
Mateos L, Ismail MAM, Gil-Bea FJ, et al. Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease [J]. J Alzheimers Dis, 2011, 24(4): 669-679.
|
| 27 |
Jiang X, Guo M, Su J, et al. Simvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro [J]. Int J Alzheimers Dis, 2012, 2012: 109324.
|
| 28 |
Zhao XS, Peng J, Wu Q, et al. Imbalanced cholesterol metabolism in Alzheimer's disease [J]. Clin Chim Acta, 2016, 456: 107-114.
|
| 29 |
Ishikawa M, Stokes KY, Zhang JH, et al. Cerebral microvascular responses to hypercholesterolemia: roles of NADPH oxidase and P-selectin [J]. Circ Res, 2004, 94(2): 239-244.
|
| 30 |
Doddy RS, Massman PJ, Mawad M, et al. Cognitive consequences of subcortical magnetic resonance imaging changes in Alzheimer's disease: comparison to small vessel ischemic vascular dementia [J]. Neuropsychiatry Neuropsychol Behav Neurol, 1998, 11(4): 191-199.
|
| 31 |
Scheltens P, Barkhof F, Valk J, et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity [J]. Brain, 1992, 115(Pt 3): 735-748.
|
| 32 |
Stewart PA, Hayakawa K, Akers MA, et al. A morphometric study of the blood-brain barrier in Alzheimer's disease [J]. Lab Invest, 1992, 67(6): 734-742.
|
| 33 |
Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond [J]. Nat Rev Neurosci, 2011, 12(5): 284-296.
|
| 34 |
Bournat JC, Brown CW. Mitochondrial dysfunction in obesity [J]. Curr Opin Endocrinol Diabetes Obes, 2010, 17(5): 446-452.
|
| 35 |
Reddy PH, Yin X, Manczak M, et al. Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer's disease [J]. Hum Mol Genet, 2018, 27(14): 2502-2516.
|
| 36 |
Netto MB, de Oliveira Junior AN, Goldim M, et al. Oxidative stress and mitochondrial dysfunction contributes to postoperative cognitive dysfunction in elderly rats [J]. Brain Behav Immun, 2018, 73: 661-669.
|
| 37 |
Power MC, Rawlings A, Sharrett AR, et al. Association of midlife lipids with 20-year cognitive change: a cohort study [J]. Alzheimers Dement, 2018, 14(2): 167-177.
|
| 38 |
Feinkohl I, Janke J, Hadzidiakos D, et al. Associations of the metabolic syndrome and its components with cognitive impairment in older adults [J]. BMC Geriatr, 2019, 19(1): 77.
|
| 39 |
Crichton GE, Elias MF, Davey A, et al. Higher HDL cholesterol is associated with better cognitive function: the Maine-Syracuse study [J]. J Int Neuropsychol Soc, 2014, 20(10): 961-970.
|
| 40 |
Liu L, Zhang C, Lv X, et al. Sex-specific associations between lipids and cognitive decline in the middle-aged and elderly: a cohort study of Chinese adults [J]. Alzheimers Res Ther, 2020, 12(1): 164.
|
| 41 |
Yu Y, Yan P, Cheng G, et al. Correlation between serum lipid profiles and cognitive impairment in old age: a cross-sectional study [J]. Gen Psychiatr, 2023, 36(2): e101009.
|
| 42 |
Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial [J]. Lancet, 2017, 390(10106): 1962-1971.
|
| 43 |
Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials [J]. J Am Coll Cardiol, 2017, 69(5): 471-482.
|
| 44 |
Gaba P, O'Donoghue ML, Park JG, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE [J]. Circulation, 2023, 147(16): 1192-1203.
|
| 45 |
Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review [J]. Ann Intern Med, 2013, 159(10): 688-697.
|
| 46 |
Bajaj NS, Patel N, Kalra R, et al. Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons [J]. Eur Heart J Qual Care Clin Outcomes, 2018, 4(2): 132-141.
|